Diagnosis and treatment with steroids for patients with Duchenne muscular dystrophy: Experience and recommendations for Mexico;Diagnóstico y tratamiento con esteroides de pacientes con distrofia muscular de Duchenne: Experiencia y recomendaciones para México

Revista de Neurologia

Volumn 57, Issue 10, 2013, Pages 455-462

  Vázquez Cárdenas, Norma A ^a,b   Ibarra Hernández, Francisco ^a,c   López Hernández, Luz B ^a,f   Escobar Cedillo, Rosa E ^g   Ruano Calderón, Luis A ^e   Gómez Díaz, Benjamín ^g   García Calderón, Noemí ^a   Carriedo Dávila, M Fernanda ^f   Rojas Hurtado, Liliana G ^f   Luna Padrón, Emilia ^d   Coral Vázquez, Ramón M ^h  

^a Asociación de Distrofia Muscular de Occidente A C   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d Gait Analysis Laboratory   (Mexico)

^e Hospital General de Durango   (Mexico)

^f CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^g SECRETARÍA DE SALUD   (Mexico)

^h INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

Author keywords

Deflazacort; DMD gene; Duchenne's muscular dystrophy; Dystrophin; Prednisone; Steroids

Indexed keywords

DYSTROPHIN; STEROID;

ARTICLE; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; MEXICO; MOBILIZATION; MUSCLE BIOPSY; QUALITY OF LIFE;

ADRENAL CORTEX HORMONES; CAREGIVERS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DYSTROPHIN; HEART DISEASES; HUMANS; HYPERGLYCEMIA; IMMUNOSUPPRESSION; INCIDENCE; MALE; MEXICO; MOLECULAR DIAGNOSTIC TECHNIQUES; MUSCULAR DYSTROPHY, DUCHENNE; OBESITY; PATIENT CARE TEAM; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; RESPIRATORY INSUFFICIENCY; RESPIRATORY THERAPY;

EID: 84887834455     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5710.2013380     Document Type: Article

References (45)

1. Goemans NM, Tulinius M, Van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N, et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-22.
2. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918-28.
3. Van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357: 2677-86.
4. Instituto Nacional de Estadística, Geografía e Informática, INEGI 2010. México en cifras. URL: http://www.inegi.gob.mx. [26.07.2013].
5. Gómez-Díaz B, Rosas-Vargas H, Roque-Ramírez B, Meza- Espinoza P, Ruano-Calderón LA, Fernández-Valverde F, et al. Immunodetection analysis of muscular dystrophies in Mexico. Muscle Nerve 2012; 45: 338-345.
6. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009; 132: 3175-86.
7. Moxley RT 3rd, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010; 25: 1116-29.
8. Ishikawa Y, Miura T, Ishikawa Y, Aoyagi T, Ogata H, Hamada S, et al. Duchenne muscular dystrophy: survival by cardiorespiratory interventions. Neuromuscul Disord 2011; 21: 47-51.
9. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9: 77-93.
10. Biggar WD. Duchenne muscular dystrophy. Pediatr Rev 2006; 27: 83-8.
11. López-Hernández, LB, Vázquez-Cárdenas NA, Luna-Padrón E. Distrofia muscular de Duchenne: actualidad y perspectivas de tratamiento. Rev Neurol 2009; 49: 369-75.
12. Álvarez-Leal M, Morales-Aguilera A, Pérez-Zuno JA, Segura- Romero S, Quiroz-Góngora MC, Paredes-García A. Relations between delayed diagnosis and forms of onset in Duchenne muscular dystrophy. Gac Med Mex 1994; 130: 459-64.
13. Cyrulnik SE, Fee RJ, De Vivo DC, Goldstein E, Hinton VJ. Delayed developmental language milestones in children with Duchenne's muscular dystrophy. J Pediatr 2007; 150: 474-8.
14. Mathews KD, Cunniff C, Kantamneni JR, Ciafaloni E, Miller T, Matthews D, et al. Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): case definition in surveillance for childhood-onset Duchenne/Becker muscular dystrophy. J Child Neurol 2010; 25: 1098-02.
15. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34: 135-44.
16. López-Hernández LB, Ayala-Madrigal ML, Van Heusden D, Estrada-Mena FJ, Canto P, Sandoval-Ramírez L, et al. Mejoras en el diagnóstico de distrofinopatías: ¿qué hemos aprendido después de 20 años? Rev Neurol 2011; 52: 239-49.
17. Almomani R, Van der Stoep N, Bakker E, Den Dunnen JT, Breuning MH, Ginjaar IB. Rapid and cost effective detection of small mutations in the DMD gene by high resolution melting curve analysis. Neuromuscul Disord 2009; 19: 383-90.
18. Abbs S, Tuffery-Giraud S, Bakker E, Ferlini A, Sejersen T, Mueller CR. Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. Neuromuscul Disord 2010; 20: 422-7.
19. Coral-Vázquez R, Arenas D, Cisneros B, Peñaloza L, Kofman S, Salamanca F, et al. Analysis of dystrophin gene deletions in patients from the Mexican population with Duchenne/ Becker muscular dystrophy. Arch Med Res 1993; 24: 1-6.
20. González-Herrera L, Gamas-Trujillo PA, García-Escalante MG, Castillo-Zapata I, Pinto-Escalante D. Identificación de deleciones en el gen de la distrofina y detección de portadoras en familias con distrofia muscular de Duchenne/Becker. Rev Neurol 2009; 48: 66-70.
21. López-Hernández LB, van Heusden D, Soriano-Ursúa MA, Figuera-Villanueva L, Vázquez-Cárdenas NA, Canto P, et al. Discordancia genotipo-fenotipo en un paciente con distrofia muscular de Duchenne por una nueva mutación: hipótesis de la función de amortiguación de la distrofina. Rev Neurol 2011; 52: 720-4.
22. Schwartz M, Hertz JM, Sveen ML, Vissing J. LGMD2I presenting with a characteristic Duchenne or Becker muscular dystrophy phenotype. Neurology 2005; 64: 1635-7.
23. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, Van Deutekom J, Van Ommen GJ, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 2009; 30: 293-9.
24. Pascual-Pascual SI. Tratamiento con oligonucleótidos antisentido en la enfermedad de Duchenne. Rev Neurol 2012; 54 (Supl 3): S31-9.
25. Schwartz M, Dunø M, Palle AL, Krag T, Vissing J. Deletion of exon 16 of the dystrophin gene is not associated with disease. Hum Mutat 2007; 28: 205.
26. Bushby K, Lochmüller H, Lynn S, Straub V. Interventions for muscular dystrophy: molecular medicines entering the clinic. Lancet 2009; 374: 1849-56.
27. Schram G, Fournier A, Leduc H, Dahdah N, Therien J, Vanasse M, et al. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Coll Cardiol 2013; 61: 948-54.
28. Angelini C. The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle Nerve 2007; 36: 424-35.
29. McAdam LC, Mayo AL, Alman BA, Biggar WD. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myol 2012; 31: 16-20.
30. Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One 2013; 8: e52512.
31. Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr 2001; 138: 45-50.
32. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006; 16: 249-55.
33. Biggar WD, Politano L, Harris VA, Passamano L, Vajsar J, Alman B, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 2004; 14: 476-82.
34. Houde S, Filiatrault M, Fournier A, Dubé J, D'Arcy S, Bérubé D, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008; 38: 200-6.
35. Merlini L, Gennari M, Malaspina E, Cecconi I, Armaroli A, Gnudi S, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012; 45: 796-802.
36. Griggs RC, Herr BE, Reha A, Elfring G, Atkinson L, Cwik V, et al. Corticosteroids in Duchenne muscular dystrophy: Major variations in practice. Muscle Nerve 2013; 48: 27-31.
37. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008; 1: CD003725.
38. Moxley RT 3rd, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005; 64: 13-20.
39. Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000; 23: 1344-1347.
40. Walter MC, Reilich P, Thiele S, Schessl J, Schreiber H, Reiners K, et al. Treatment of dysferlinopathy with deflazacort: a double-blind, placebo-controlled clinical trial. Orphanet J Rare Dis 2013; 8: 26.
41. Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-40.
42. Nuorti JP, Whitney CG; Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children -use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine-. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59: 1-18.
43. Gedalia A, Shetty AK. Chronic steroid and immunosuppressant therapy in children. Pediatr Rev 2004; 25: 425-34.
44. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9: 177-89.
45. World Health Organization. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-height and body mass index-for-age: methods and development. Geneva: WHO; 2006. URL: http://www.who.int/childgrowth/publications/technical_report_pub/en/index.html. [26.07.2013].